The board of directors of CARsgen Therapeutics Holdings Limited announced that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical resection.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 HKD | -0.97% | +1.84% | -6.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.15% | 454M | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.08% | 22.27B | |
-12.64% | 22.22B | |
-5.15% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- 2171 Stock
- News CARsgen Therapeutics Holdings Limited
- CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration